Blocking EGFR Activation with Anti-EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Cancer is characterized by overproduction of growth factors like epidermal growth factor (EGF).
• Epidermal growth factor receptor (EGFR)-targeted therapies show clinical success but are limited by drug-resistant mutations.
• A need exists for novel therapeutic strategies to overcome EGFR inhibitor resistance.

Purpose of the Study:

• To develop and characterize novel direct inhibitors of EGF.
• To investigate the mechanism of action of these inhibitors at a biophysical and cellular level.
• To assess their efficacy in inhibiting EGFR phosphorylation and downstream signaling in cancer cells.

Main Methods:

• Generation of camelid-derived single-domain antibodies (Nbs) as direct EGF inhibitors.
• Detailed biophysical investigation of Nb-EGF interactions, including binding kinetics and thermodynamics.
• Assessment of cellular EGFR phosphorylation inhibition by Nbs.

Main Results:

• Novel Nbs were identified as direct inhibitors of EGF, preventing EGFR phosphorylation.
• Distinct binding kinetics and thermodynamic profiles were observed between the two lead Nbs.
• Both Nbs demonstrated efficient inhibition of cellular EGFR phosphorylation, effectively blocking the oncogenic pathway.

Conclusions:

• Camelid-derived Nbs represent a promising new class of direct EGF inhibitors for cancer therapy.
• These Nbs offer a novel mechanism of action to overcome resistance to existing EGFR-targeted therapies.
• The biophysical and cellular data validate the efficacy of these Nbs in halting a key cancer-promoting pathway.